Someone must be topping up :) nai etc |
Perhaps because all railway lines end up in London? |
Dom,
I'm probably geographically biased with this one, but I wonder how much it costs to host an AGM in London? If they have the capability to host it in Oxford for little cost and minimal disruption then why not? |
Plutonian,
I'm not sure that we're differing here. I'm sure I remember (it is a long time now) JD when we bought the old Cobra building explaining that we cancelled our RetinoStat trial order when TRIST halted, then when Sanofi did the ocular deal we immediately reordered, but as well as losing our place and deposit, it also cost us 13 months as we went to the back of the queue again.
What I am saying is that whilst OXB made it very plain initially that it was for security of supply with our own drugs (Novartis later changing that and then our whole business) those cell lines and later the suspension tech can still only do some very specialised work. It could never do what the questioner suggested. |
I attended the AGMs for more than a decade, and valued the opportunity to speak to the board personally, and look them in the eyes. I didn't go Coid year of course, the following year was also 'virtual'. Last year they decided to make it in Oxford. This said to me "We don't want private investors to come so we won't make it easy or convenient".
Attendance over. |
Yes I enjoyed the excuse to visit London and afterwards meet friends at the India Club for their great dosaAn industrial estate outside of Oxford is just not the same Anyway no doubt they will be providing limousines to whisk shareholders from the railway station to the meeting |
Morning Dom
RE: the AGM
In the last few years (pre covid) I did get the impression (only from 1 or 2 members of the board) that individual PI's that turned up to the AGM and asked difficult questions were frowned upon when all they wanted was to get their resolutions passed.
I remember once when a disillusioned shareholder was questioning yet another dilution when a board member replied something along the lines of ...
'Well if you are looking for share price growth or a quick buck you are invested in the wrong company' I must admit to being gobsmacked at that and even questioned myself about whether or not to sell up and move on but that was a good few years ago.
I have to say though that I did enjoy the tea and biscuit session after the official meeting had finished much more fruitful for gathering titbits of information and being able to 'look them in the eyes' for hints or meaningful phrases.
Not sure if I will be going to Oxford this year though. |
Afternoon Northstand. (I've stopped going to AGMs now, so if you are going, I won't be there! I feel that this management do not welcome shareholder interest.)
In fact, I think they are trying to 'bore us away' (tell us nothing and we might just go away!). |
Morning Dom
Don't be fooled by the trades all being marked though as sales.
This morning I put a buy order in of 2600 shares at a 325 limit price when the price was 326/321
the bid immediately rose to 326/325,shortly after 2 AT trades went through of
1991 & 609 shares at 325p and were marked as 2 sales (which is also kind of correct) when in fact it was also my order being filled.
I'm still convinced (like Harry) that something big is brewing in the background
so wanted to make sure I was topped up just in case.
There seems to be big support around 315 which gives me confidence that this won't drift again like in previous months. |
Every morning it opens, then drops, before working its way up to the open price or thereabouts. Who I wonder is selling at start of day? |
Apologies if posted before: |
An AZ connection would be fantastic H.
CF gene therapy 4D-710 improves lung function, data show |
Yes, scale up is going from doing a process in test tubes and peach-tree dishes to making it work in a 10,000 litre bioreactor. Interestingly for the chemists and biotechs, it tends to be very non-linear, so that what you have to do to make it work, and what you get, in 10 litres is often not a simple predictor of what you get in 50 litres etc etc. That's living organisms for you. |
I think it means scaling up as part of process development - from the concept to proof of concept to actually actually being able to make a product in enough quantity for lab experiments then clinical trials, then production - i.e. the continual next step in any process upon success at the previous level (trickier than it sounds). |
'process scale up'. Scaling up suggests expansion, always a + |
 Technical Writer, Process Development
Date: 7 Jun 2024
Location: Oxford, GB
Company: oxfordbiom
We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you.
We are currently recruiting for a Technical Writer join the Process Development team (PD). The purpose of this role is to collaborate with Scientists in the effective reporting of experimental data from work carried out within the PD department, to support the delivery of feasibility studies, process development, process scale up, technical transfer and process characterisation activities.
Oxford Biomedica’s Process Development team consists of experienced Scientists, Scientific Assistants, Engineers & Writers that have extensive expertise in all aspects of upstream and downstream development. PD take processes from the laboratory “bench” scale and apply process expertise and engineering fundamentals for delivery to Manufacturing.
Your responsibilities in this role would be:
The authoring of clear and concise documentation including protocols and scientific reports to support Upstream and Downstream process development activities.
Review documentation including protocols and technical reports prior to issue to clients.
Produce and maintain technical report templates and outlines
Maintain technical report writing procedures and guidelines.
Function as department subject matter expert within Technical Writing, including training the team
Maintain a high standard of record keeping and documentation so that information is clearly captured, disseminated, and reported.
Disseminate critical findings which may have a business impact to other departments within the company.
Maintain a high ethical standard and a commitment to producing high quality work.
Ensure all scientific or proprietary data is submitted or recorded in appropriate official documentation. |
I suppose the literal million dollar question here Marcus, would be to ask if AZ (or one of the CAR-T biotech companies it has swallowed) is a confidential / undisclosed OXB vector client.
It would be very nice if that was the case.
Remember at the results they said 51 programmes with 35 clients (which will be more by now, but the results was the last figure we knew).
So out of those 35 we have 15 or 16 where we can be reasonably sure of a name:-
Arcellx
Beam Therapeutics
BMS (Juno)
Boehringer Ingelheim
Cabaletta Bio
CARGO Therapeutics
Coave Therapeutics (Old ABL)
GC Cell (Green Cross Singapore)
Geovax (Old ABL)
Immatics
Immune Design (bought by Merck)
Kyverna
Novartis
Orchard Therapeutics
RD-Biotech (Old ABL)
Sardocor
Which of course leaves 19 or 20 (at the end of April) where we could only guess. |
Armouring Car Ts may be the answer.
“armouring” element on C-CAR031 comprises a co-expressed dominant-negative TGFβ receptor that’s been truncated, so it lacks an intracellular domain necessary for downstream signalling. This feature is designed to protect the Car-T cells from TGFβ-driven immunosuppression. |
A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.
“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview. |
They are publishing early data PB.
See post 7906
Certainly won't do us any harm. |
We are in a very tight holding pattern so sifting the tea leaves to find any hopes of an exit are for passing the time of day - not taking it all too seriously alongside the technical charting stuff.... |
How big was the 'chunky buy'? Is it feasible that the 20-50k lots dumped were small enough to make the buy decently profitable? |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
